STAT+: A standing ovation for RevMed, and caution for Akeso

STAT PlusBiotech A standing ovation for RevMed, and caution for Akeso This is STAT’s ASCO in 30 Seconds newsletter Manage alerts for this article Email this article Share this article By Adam Feuerstein, Matthew Herper, Katherine MacPhail, and Angus ChenMay 31, 2026 Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Matthew Herper[email protected]Matthew Herper covers medical innovation — both its promise and its perils.Katherine MacPhail[email protected]Katherine MacPhail is a reporter and editorial events programmer for STAT.Angus Chen[email protected]Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08. You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. Oncologists are capable of some raucous applause, but they don’t bestow it upon just anyone. Today saw one of those coveted standing ovations, and the hoots and cheers were not held for the end.Advertisement The plenary may have passed, but ASCO isn’t over yet— we’ll be back tomorrow with our final newsletter installment, and you can catch our virtual recap on Wednesday. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In ASCO, Cancer, drug development, Drug prices, global health, Pharmaceuticals, STAT+ Submit a correction requestReprints Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Matthew Herper Senior Writer, Medicine, Editorial Director of Events Matthew Herper covers medical innovation — both its promise and its perils. Katherine MacPhail Reporter, Live Journalism Katherine MacPhail is a reporter and editorial events programmer for STAT. Angus Chen Cancer Reporter Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Pharma May 31, 2026 Ultra-low doses could bring costly cancer treatments to more patients in poorer countries Biotech May 31, 2026 STAT Plus: Practice-changing results reported for Revolution Medicines pancreatic cancer drug Advertisement Biotech May 31, 2026 STAT Plus: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer Biotech May 31, 2026 STAT Plus: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds Biotech May 30, 2026 STAT Plus: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA Subscriber Picks